Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doppler ultrasound prediction of response to T-VEC in melanoma
2018-002677-22Phase 2Active
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jul 2019
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec in melanoma, sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Primary: correlation of vascularization with clinical response. Started Jul 2019; status: active.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-002677-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002677-22.